Pharma BD Deal Intelligence
Alexion is paying $8.4 billion to acquire Synageva, one of the largest premiums paid to any company over $5 billion in market cap since 1995, for access to a…
Alexion acquired Synageva BioPharma for $8.4B for Kanuma (sebelipase alfa).
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Alexion acquired Synageva BioPharma for $8.4B for Kanuma (sebelipase alfa).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. / Synageva BioPharma (this deal) | 2015 | $8.4B | 36 |
| Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB | 2018 | $855M | 20 |
| Alexion Pharmaceuticals Inc. / Syntimmune, Inc. | 2018 | $1.2B | 14 |
| Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. | 2020 | $1.4B | — |
| Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. | 2019 | $1.2B | — |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
← Browse all deals · How we score deals
More: 2015 deals · Alexion Pharmaceuticals Inc. deals · Rare Disease deals